Insulin detemir lowers the risk of hypoglycaemia and provides more consistent plasma glucose levels compared with NPH insulin in Type 1 diabetes

What Was Tested

Researchers studied Insulin Detemir and NPH Insulin (isophane) in this randomized controlled trial publication.

Who Took Part

The abstract describes 130 individuals taking part.

The age groups tagged for this paper are adults, both men and women.

In this multinational, open-label, cross-over trial, 130 individuals with Type 1 diabetes received detemir and NPH twice daily in a randomized order in combination with premeal insulin aspart (IAsp) during two 16-week treatment periods.

How the Study Was Run

In design terms this was a randomized, open-label and crossover study.

The individuals were allocated by chance, so the Insulin Detemir group and the comparison group should start out alike.

Everyone knew when Insulin Detemir was being given (open label), which is simpler to run but leaves more room for expectations to affect what is reported.

Each person switched between Insulin Detemir and the comparison at some point, usually with a gap in between.

Risk of hypoglycaemia was based on self-measured plasma glucose (SMPG) and self-reported episodes during the last 10 weeks of each period.

What Was Measured

PubMed files the paper under topics including Blood Glucose, Diabetes Mellitus, Type 1, Glycated Hemoglobin, Hypoglycemia, Hypoglycemic Agents, Insulin and Insulin Aspart.

What This Means in Plain Language

The paper is a randomized, open-label and crossover study of Insulin Detemir and NPH Insulin (isophane) in 130 individuals.

Its findings take up roughly 6 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2006 (Diabetic medicine : a journal of the British Diabetic Association), a journal based in England.

More context: the Insulin Detemir compound page and the NPH Insulin (isophane) compound page.